• UVM Cancer Center, Larner College of Medicine 

• Northern Light Eastern Maine Medical Center Cancer Care

• Dartmouth Cancer Center

• UVM Cancer Center

• Beth Israel Lahey Health Exeter

https://asco.quorum.us/campaign/56411/

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Latest FDA Approval

• October 10 - FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
• October 3 - FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
• September 27 - FDA approves selpercatinib for medullary thyroid cancer with a RET mutation
• September 25 - FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
• September 20 - FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
• September 19 - FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
• September 17 - FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
• September 17 - FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
• September 12 - FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
• August 19 - FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer
• August 15 - FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer
• August 14 -FDA approves axatilimab-csfr for chronic graft-versus-host disease 
• August 6 - FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
• August 2 - FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma
• August 1 - FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
• July 30 - FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma

Package/Label Updates

Code Updates

• Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
  

Other Updates